Our Vision In Action

Our platform enables discovery of high-quality, novel molecules more rapidly, at lower cost

Our world-class drug discovery team is leveraging our computational platform and massive computing power to advance our preclinical pipeline and a portfolio of programs in collaboration with leading biotech and pharmaceutical companies.

Pipeline
Program DiscoveryIND-EnablingCLINICAL Rights
Rights
Program MALT1
Relapsed / Resistant
Non-Hodgkin's Lymphoma
IND-Enabling
 Schrödinger
Program CDC7
Hematological Cancers and
Solid Tumors
Discovery
 Schrödinger
Program WEE1
Gynecological Cancers and
other Solid Tumors
Discovery
 Schrödinger
Program Undisclosed Program
Oncology
 
Discovery
 Schrödinger
Program Undisclosed Program
Immunology
 
Discovery
 Schrödinger
Rights
Program SOS1 / KRAS
KRAS-Driven Cancers
 
Discovery
 Schrodinger and Bristol Myers Squibb
Program Undisclosed Programs
Oncology, Immunology and
Neurology
Discovery
 Schrodinger and Bristol Myers Squibb
Rights
Program DNA Damage Response
Oncology
Discovery
 Schrodinger and ZAI Lab
Rights

Collaborative Programs

We have teamed up with venture capitalists, leading academics, and biopharma companies around the globe to establish research collaborations and co-found startups. We currently have collaborative drug discovery programs with more than 10 companies. 

Some of the companies include Ajax Therapeutics, Bright Angel Therapeutics, Faxian Therapeutics, Morphic Holding, Nimbus Therapeutics, Ono Pharmaceutical, Sanofi, ShouTi , Sun Pharma Advanced Research Company (SPARC), Takeda,  and TB Alliance. These programs are being advanced by our collaborators in diverse therapeutic areas, including oncology, antifungals, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, neurodegenerative disease, and tuberculosis. 

These collaborations have to date resulted in two FDA approved drugs and multiple programs that have advanced into clinical trials. 

Back To Top